tetano
Editor, Senior Moderator
Int J Antimicrob Agents. 2020 Mar 13:105944. doi: 10.1016/j.ijantimicag.2020.105944. [Epub ahead of print]
Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
Author information
Abstract
In December 2019, a new coronavirus, named SARS-CoV-2, has emerged from China causing pneumonia outbreaks first in the Wuhan region and have now spread worldwide because of its probable high transmission efficiency. Due to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococci infection, previously showed efficacy to inhibit the first stage of MERS-coronarivus viral cycle in human cells. This activity is conserved on the SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
COVID-19; Drug repurposing; SARS-CoV-2; Teicoplanin
PMID:32179150DOI:10.1016/j.ijantimicag.2020.105944
Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
Author information
Abstract
In December 2019, a new coronavirus, named SARS-CoV-2, has emerged from China causing pneumonia outbreaks first in the Wuhan region and have now spread worldwide because of its probable high transmission efficiency. Due to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococci infection, previously showed efficacy to inhibit the first stage of MERS-coronarivus viral cycle in human cells. This activity is conserved on the SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
COVID-19; Drug repurposing; SARS-CoV-2; Teicoplanin
PMID:32179150DOI:10.1016/j.ijantimicag.2020.105944